

JOHN A. LAHIVE, JR., 1908-1997
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DECONTI, JR.
ANN LAMFORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DEANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
CEBRA J. MILASINIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAND D. DETWELER

CYNTHIA L. KANK, Ph.D.
MEGANE E. WILLIAMS, Ph.D.
RICHARD AND
MICHAEL PHILLIPS*
LISA M. DIROCCO
HATHAWAY P. RUSSELL**
MARIA LACCOTRIPE ZACHARAK, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SCROGS
PETER W. DINI, Ph.D.
EUHOOON LEE
JENNIFER K. ROSENFELD
ALLAN TAMESHITI, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTINE E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

March 28, 2002

Commissioner for Patents
Box Sequence
Washington, D.C. 20231

Re: U.S. Continuation-in-Part Patent Application Serial No. 09/847,940
Title: "Anti-Inflammatory Compounds and Uses Thereof"
Inventors: Michael J. May and Sankar Ghosh
Filing Date: May 2, 2001
Attorney Docket No. PPI-117CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Transmittal Letter for Diskette Containing Sequence Listing;
3. Paper Copy of Sequence Listing (Pages 1-7);
4. Diskette Containing Computer Readable Copy of Sequence Listing;
5. Copy of Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (Formalities Letter);
6. Statement of Limited Recognition Under 37 C.F.R. §10.9(b) for Maria C. Laccotripe;
7. Pre-paid acknowledgment postcard.

No additional costs are believed to be due in connection with the filing of this Response to Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. However, please charge any necessary fees in connection with the enclosed filing to our Deposit Order Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. *For this purpose, a duplicate of this sheet is attached.*


Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Sequence, Washington, DC 20231 on:

March 28, 2002
Date

Maria C. Laccotripe
Limited Recognition Under 37 C.F.R. § 10.9(b)

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By: 
Maria C. Laccotripe, Ph.D.
Limited Recognition Under 37 C.F.R. §10.9(b)
Attorney for Applicants
28 State Street
Boston, MA 02109-1784
(617) 227-7400



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the application of: Michael J. May and
Sankar Ghosh

Group Art Unit: 1645

Examiner: Not Yet Assigned

Serial No.: 09/847,940

Filed: May 2, 2001

For: "Anti-Inflammatory Compounds and Uses
Thereof"

Attorney Docket No.: PPI-117CP

Commissioner for Patents
BOX SEQUENCE
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on the date set forth below.

March 28, 2001

Date of Signature and of Mail Deposit

By:

Maria C. Laccotripe, Ph.D.

Limited Recognition Under 37 C.F.R. §10.9(b)

Attorney for Applicants

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Dear Sir:

This is in response to the Examiner's communication dated February 22, 2002.

REMARKS


In the Notice to Comply With Requirements For Patent Applications Containing
Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated February 22, 2002

(hereinafter "Notice"), the Examiner requires that Applicants submit a substitute computer readable form (CRF) copy of the "Sequence Listing" for the above-identified application.

Accordingly, Applicants submit herewith a computer-readable form (diskette) of the Sequence Listing for the above-identified patent application. In addition, for the Examiner's convenience, Applicants submit herewith a paper copy of the Sequence Listing (pages 1-7). The material on the aforementioned diskette is identical in substance to the sequence listing appearing on pages 1-7 of the Sequence Listing which is submitted herewith.

No new matter has been added to the application.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Maria C. Laccotripe, Ph.D.
Limited Recognition Under 37 C.F.R. §10.9(b)
Attorney for Applicants

28 State Street
Boston, MA 02109
telephone: (617) 227-7400
facsimile: (617) 742-4214

Dated: March 27, 2002

28 (MCL)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D. C. 2023
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09 847,940	05 02 2001	Michael J. May	PPI-117CP

000959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109

CONFIRMATION NO. 6156

FORMALITIES LETTER



OC000000007520699

Date Mailed: 02/22/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE